Aprea Therapeutics Future Growth
Future criteria checks 2/6
Aprea Therapeutics's earnings are forecast to decline at 8.2% per annum while its annual revenue is expected to grow at 57.4% per year. EPS is expected to grow by 24.7% per annum.
Key information
-8.2%
Earnings growth rate
24.7%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 57.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -21 | N/A | N/A | 3 |
| 12/31/2025 | 1 | -19 | N/A | N/A | 3 |
| 12/31/2024 | 1 | -17 | N/A | N/A | 2 |
| 9/30/2024 | 1 | -14 | -14 | -14 | N/A |
| 6/30/2024 | 1 | -13 | -14 | -14 | N/A |
| 3/31/2024 | 1 | -13 | -13 | -13 | N/A |
| 12/31/2023 | 1 | -14 | -12 | -12 | N/A |
| 9/30/2023 | 1 | -13 | -13 | -12 | N/A |
| 6/30/2023 | 0 | -14 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -109 | -22 | -22 | N/A |
| 12/31/2022 | N/A | -113 | -25 | -25 | N/A |
| 9/30/2022 | N/A | -118 | -31 | -31 | N/A |
| 6/30/2022 | N/A | -123 | -33 | -33 | N/A |
| 3/31/2022 | N/A | -35 | -34 | -34 | N/A |
| 12/31/2021 | N/A | -37 | -38 | -38 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APRE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APRE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APRE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APRE's revenue (57.4% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: APRE's revenue (57.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APRE's Return on Equity is forecast to be high in 3 years time